

Company Overview

- A company on a mission to reverse and cure age-related diseases using a unique telomerase protocol program
- Disrupt global healthcare and the pharmaceutical industry with telomerase therapy
- Deliver therapeutic, knowledge based, preventative healthcare with innovative AI+VR strategy

Contact Information

- 250 Monroe NW Suite 400
- Grand Rapids, MI 49503
- Email: info@telocyte.com
- www.telocyte.com

Investment Ask

- \$25M

Use of Funds

- Clinical Program: 64%
- Team Building: 11%
- Tech Platform: 11%
- AI Therapeutics + VR Clinic: 4%
- Other: 10%


Leadership Team



Michael Fossel
President & Founder



Peter Rayson
CEO & Founder



Rajesh Shukla
CSO



Michelle Hylan
COO



Georgi Gospodinov
CTO



Radomir Julina
CPO

Key Relationships

- Houston Methodist (clinical trials)
- Thermo Fisher (drug manufacturing, CRO)

Executive Summary

Investment Presentation Access [Here](#)

The first and only Human Telomerase Protocol to cure human age-related diseases. Telocyte was founded by [Michael Fossel](#), MD, PhD, the world's leading expert on cellular aging and age-related diseases. Telocyte's proprietary telomerase-based protocol will reverse cell aging in humans, curing age-related diseases.

Executive Summary

Mission

"Reverse age-related diseases, starting with Alzheimer's"

Vision

"Deliver an age-reversing therapeutic worldwide through telomerase therapy"

Problem and Solution

Problem

- Age-related diseases are a global crisis
- Alzheimer's has no cure, a leading cause of death, 500k/year
- \$42B in drug R&D over the past 30 years have yielded no treatment

Current Efforts

- Current drug R&D efforts target the symptoms, not the cause
- The only success is with detection & diagnostics
- 1 out of over 200 drugs approved in the past decade: 99.6% failure rate

Telocyte's Solution

- The first human telomerase protocol for treatment and cure Alzheimer's and age-related diseases
- Proven effect in animals, and human cells/tissue



Revenue Model/Market Opportunity

Revenue

- **Initial Price:** \$104,600/5-yearly dose
- **Conservative, Cumulative 10-year Revenue Projection:** \$52B
- **Serviceable Population (SAM):** 10% of TAM



Market Opportunity

- **Alzheimer's** costs \$1.7T by 2030
- **Other dementias** costs \$1.1T by 2030
- **Cardiovascular Disease** costs \$1.0T by 2035

Distribution Plan

- Licensing agreements with NHS and Big Pharma covering the costs of servicing the global Alzheimer's population

Revenue Growth

5 Years Conservative estimates

\$7.0M → \$2.4B

- \$13B + \$2.4B (2nd dose) in year 10

Competitive Analysis

Companies are targeting the symptoms

β Amyloid

- Eli Lilly
- Biogen
- Alzheon
- Vivoryon
- Priaboid

Tau

- Voyager Therapeutics
- AC Immune SA
- Denali Therapeutics
- Priaboid

Mitochondria

- Alecor
- Amylyx Pharma
- Codiak BioSciences
- Oracion Biotech
- Tetra

Telocyte is targeting the underlying cause
Telomerase



Telocyte Products

- **Therapeutic:** Deliver Telocyte's proprietary telomerase-based protocol to reverse cell aging, curing age-related diseases, and a personalized therapeutic program
- **AI + VR Clinic:** deliver AI-enhanced diagnostics, precision preventative healthcare, and virtual healthcare management to improve long-term outcome and reduce hospitalization
- **Knowledge Platform:** Provide significant clinical cost reduction, compliant and effective clinical execution, and enable granular consent to increase patient engagement